Download the ESMO 2012 Abstract Book - Oxford Journals

Annals of Oncology subject index
interstitial pneumonitis, ix283 (855P)
interstitial pulmonary disorder, ix226 (673P)
interval debulking surgery, ix332 (1013)
intestine, ix69 (152P)
intralesional, ix371 (1137P)
intraperitoneal chemotherapy, ix233 (698P), ix234
(702P), ix254 (774)
intratechal trastuzumab, ix141 (404)
intratumor heterogeneity, ix69 (151P), ix51
(83IN)
intratumoral heterogeneity, ix373 (1146), ix531
(1656P)
intravenous iron, ix504 (1561P), ix523 (1627)
intravisical chemotherapy, ix290 (882)
intrinsic subtypes, ix131 (366P)
invasion, ix345 (1055)
invasive lobular carcinoma, ix175 (511PD)
invasiveness, ix136 (384)
investigational, ix158 (456P)
iodine, ix522 (1626)
IPCW, ix194 (570P)
ipilimumab, ix363 (1116PD), ix364 (1117PD),
ix366 (1126P), ix366 (1126P), ix367 (1127P),
ix367 (1128P), ix368 (1129P), ix368 (1130P),
ix369 (1131P), ix369 (1132P), ix369 (1133P),
ix370 (1134P), ix372 (1143P), ix373 (1148),
ix374 (1149), ix374 (1150), ix374 (1151), ix375
(1152), ix75 (175PD), ix38 (46IN)
irinotecan, ix204 (599P), ix205 (602P), ix230
(688P), ix237 (710P), ix249 (755)
IRIS, ix202 (592P)
iron supplementation, ix523 (1627)
ISET, ix338 (1029P), ix90 (227P)
isolation perfusion, ix486 (1504P)
item response theory, ix109 (296P)
J
Japanese population, ix167 (486P), ix220 (653)
jaw osteonecrosis, ix511 (1585P), ix56 (95IN)
juvenile glioblastoma, ix147 (421P)
K
K-RAS mutation, ix530 (1652P), ix234 (703P)
K-ras status, ix80 (194P)
K-RAS, ix429 (1307P), ix216 (641)
ketoconazole, ix305 (927P)
Ki-67 antigen, ix377 (1158P), ix184 (538P)
Ki-67, ix80 (191P), ix83 (201P), ix101 (268P),
ix131 (366P)
Ki67, ix92 (233), ix112 (305)
kidney cancer, ix266 (805P), ix272 (822P), ix276
(835P), ix281 (849P)
kidney failure, ix444 (1361), ix458 (1409)
kidney, ix267 (810P), ix269 (816P), ix290 (879)
kinase inhibitor, ix433 (1324), ix124 (342P)
kinases, ix21 (1IN)
KIT exon 9 mutation, ix481 (1486PD)
knowledge about cancer, ix457 (1406)
Kochers’ thyroidectomy, ix346 (1060)
KRAS and BRAF, ix85 (208P), ix182 (532P),
ix183 (537P), ix186 (548P), ix187 (549P)
KRAS genotyping, ix85 (210P)
KRAS mutations, ix431 (1315)
KRAS wild-type metastatic colorectal cancer,
ix191 (561P), ix202 (594P)
KRAS, ix387 (1187P), ix403 (1233PD), ix427
(1302P), ix432 (1316), ix530 (1654P), ix74
(170O), ix84 (207P), ix85 (211P), ix182 (533P),
ix185 (543P), ix196 (574P)
L
L-BLP25, ix395 (1210), ix211 (622)
L861Q, ix413 (1259P)
lactobacterin, ix290 (882)
laparoscopic surgery, ix292 (888)
lapatinib resistance, ix532 (1659P)
lapatinib, ix58 (104IN), ix101 (267P), ix139 (396)
large cell neuroendocrine carcinoma (LCNEC),
ix79 (188P)
laryngeal carcinoma, ix338 (1031P)
late relapse, ix75 (176PD)
late stage, ix136 (383)
Latin America, ix65 (133IN)
LDK378, ix153 (440O)
leaflet, ix518 (1611P)
lean body mass, ix512 (1588P)
lenalidomide, ix44 (67IN)
length of hospital stay, ix354 (1085P)
lenvatinib, ix244 (737P)
leptin receptor antagonist, ix166 (483P)
leptin, ix516 (1603P), ix166 (483P)
leptomeningeal carcinomatosis, ix140 (402), ix149
(429P)
leptomeningeal metastasis, ix141 (404)
leucovorin, ix217 (646)
lidocain patch, ix521 (1622)
life extending, ix132 (369P)
limb-sparing surgery, ix486 (1504P)
linifanib, ix83 (203P), ix173 (505), ix173 (507)
liposarcoma, ix54 (93IN)
liposomal cytarabine, ix149 (429P)
liposomal doxorubicin, ix160 (462P)
liposome, ix164 (477P)
liver cancer, ix63 (125IN), ix245 (741P)
liver limited disease, ix217 (643)
liver metastases, ix358 (1100), ix370 (1136P),
ix198 (580P), ix219 (651)
liver toxicity, ix290 (880)
LKB1, ix77 (180P)
LMO4, ix531 (1655P)
lobular carcinoma, ix544 (1702)
local advanced triple negative breast cancer
(LATNBC), ix130 (361P)
local radiation-induced damages, ix311 (944P)
locally advanced breast cancer, ix120 (330P),
ix134 (377), ix135 (380), ix137 (389)
locally advanced cervical cancer, ix330 (1007)
locally advanced disease, ix241 (726P)
locally advanced head and neck cancer, ix335
(1020PD), ix341 (1039P)
locally advanced non-small cell lung cancer, ix520
(1620)
locally advanced stage III NSCLC, ix392 (1200P),
ix392 (1203P), ix330 (1007), ix330 (1007)
locally advanced, ix331 (1008), ix395 (1211),
ix238 (716P)
locally-advanced pancreas cancer, ix238 (715P)
locally-advanced pancreatic carcinoma, ix237
(711P)
longitudinal study, ix515 (1600P)
long QTc, ix173 (508)
long-term follow-up, ix522 (1624), ix148 (425P),
ix273 (826P)
long-term responders, ix125 (346P)
long-term response, ix446 (1367TiP)
long-term survival, ix412 (1256P), ix307 (933P)
long-term use, ix510 (1583P)
loss of mismatch repair protein expression, ix176
(516P)
low doses, ix139 (397)
low malignant potential tumor, ix331 (1011)
low molecular weight heparin, ix519 (1616P)
low-dose radiotherapy in lymphoma, ix353
(1081P)
low-grade lymphoma, ix353 (1081P)
LRIG, ix185 (544P)
luminal A and B, ix102 (270P)
luminal A, ix27 (13IN)
luminal B, ix27 (13IN)
lung adenocarcinoma, ix391 (1198P), ix412
(1255P), ix414 (1262P), ix432 (1318), ix444
(1362TiP), ix454 (1395P), ix92 (233)
lung cancer stem cells, ix454 (1395P)
lung cancer, ix383 (1175P), ix383 (1176P), ix385
(1180PD), ix388 (1188P), ix388 (1190P), ix396
(1214), ix414 (1264P), ix414 (1265P), ix423
(1290P), ix425 (1297P), ix430 (1310P), ix432
(1320), ix433 (1321), ix446 (1368TiP), ix457
(1406), ix497 (1538P), ix506 (1569P), ix525
(1637), ix541 (1691P), ix544 (1699P), ix73
(169O), ix544 (1701), ix76 (177PD), ix78
(183P), ix79 (188P), ix79 (190P), ix92 (235),
ix49 (78IN), ix24 (7IN)
lung metastases, ix212 (626)
lung toxicity, ix396 (1213), ix396 (1216)
lung, ix492 (1521PD)
Lungscape, ix58 (105IN)
lutenizing hormone releasing harmone, ix306
(928P), ix321 (928P)
lymph node, ix207 (611P), ix254 (773)
lymph nodes, ix387 (1184P), ix135 (381)
lymphadenectomy, ix112 (307)
lymphoid malignancies, ix353 (1082P)
lymphoma, ix352 (1079P), ix358 (1100), ix492
(1521PD), ix518 (1609P), ix44 (64IN)
lymphoplasmacytic reaction, ix99 (260P)
lymphovascular invasion (LVI), ix186 (547P)
Lynch syndrome, ix176 (516P)
M
macrocytosis, ix442 (1355)
magnetic resonance imaging (MRI), ix207 (610P)
maintenance chemotherapy, ix397 (1219), ix409
(1247P), ix486 (1503P), ix128 (356P)
maintenance pem beva, ix434 (1327)
maintenance therapy, ix393 (1206P), ix397 (1218),
ix404 (1235PD), ix417 (1271P), ix418 (1275P),
ix305 (927P)
maintenance, ix421 (1281P)
male breast cancer, ix110 (298P), ix132 (371P)
malignancies, ix492 (1521PD), ix158 (456P)
malignant ascites, ix514 (1596P), ix539 (1683P),
ix172 (504)
malignant lymphoma, ix44 (65IN)
malignant melanoma, ix365 (1120P), ix373 (1147)
malignant mesothelioma, ix469 (1447PD)
malignant pleural mesothelioma (MPM), ix78
(185P), ix496 (1533P), ix496 (1534P), ix94 (244)
malignant transformation, ix286 (864P)
malnutrition, ix350 (1069PD), ix355 (1089P),
ix356 (1091P), ix455 (1399P), ix499 (1544O),
ix511 (1587P)
MALT lymphoma, ix351 (1075P), ix352 (1076P)
mammaglobin, ix111 (304)
mammographic breast density, ix34 (35IN)
mammography screening, ix470 (1451P)
management decision, ix485 (1498P), ix237
(711P)
management of soft tissue sarcoma, ix478
(1477O)
management, ix482 (1488P), ix236 (708P)
mantle cell lymphoma, ix354 (1084P), ix359
(1107TiP), ix44 (66IN)
manual for diabetic patients, ix527 (1705)
MAP kinase, ix338 (1030P)
MAPK, ix156 (451P), ix164 (475P)
MASS criteria, ix244 (735P)
mass screening, ix53 (88IN)
mastectomy, ix477 (1476), ix137 (389)
maximum tolerated dose, ix170 (497P)
MCC, ix365 (1121P)
MCPH1, ix533 (1662P)
mCRC, ix93 (237), ix178 (518O), ix188 (554P),
ix198 (581P), ix213 (632), ix214 (633), ix217
(646), ix222 (662TiP)
mCRPC, ix311 (943P), ix312 (948), ix316
(962TiP), ix317 (965TiP)
MDM2, ix54 (93IN)
MDV3100, ix295 (896O), ix297 (899PD), ix304
(924P), ix305 (925P)
measurement of glomerular filtration rate, ix171
(500P), ix283 (857P)
media, ix66 (142IN)
Volume 23 | Supplement 9 | September 2012 doi:10.1093/annonc/mds467 | ix593